Briacell Therapeutics Corp.
(MENAFN- Baystreet) 10:09 AM EST - BriaCell Therapeutics Corp.: Announced the presentation of clinical biomarker findings from a prospective pooled analysis of patients with metastatic breast cancer treated with immune based therapies including the BriaCell regimen at the European Society for Medical Oncology Congress 2026, taking place October 23-27 in Madrid. BriaCell Therapeutics Corp.
shares T are trading unchanged at $4.84.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Comments
No comment